Enovis Corporation (ENOV)
NYSE: ENOV · Real-Time Price · USD
35.94
+0.38 (1.07%)
Jul 10, 2025, 4:00 PM - Market closed
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Total Medical Technology | 2.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Medical Technology Growth | 18.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Bracing & Support | 469.32M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Bracing & Support Growth | 5.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Other P&R | 270.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Other P&R Growth | -1.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International P&R | 357.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International P&R Growth | 1.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Reconstructive | 505.62M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Reconstructive Growth | 16.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Reconstructive | 504.05M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Reconstructive Growth | 81.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevention & Recovery Capital Expenditures | 34.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevention & Recovery Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconstructive Capital Expenditures | 146.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconstructive Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Prevention & Recovery Adjusted EBITDA | 159.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevention & Recovery Adjusted EBITDA Growth | 5.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconstructive Adjusted EBITDA | 216.92M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconstructive Adjusted EBITDA Growth | 62.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
United States | 1.25B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 7.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Foreign Locations | 861.95M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Foreign Locations Growth | 37.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|